Are Lloyds Banking Group PLC And GlaxoSmithKline plc Bargain Buys For 2016?

Why Lloyds Banking Group PLC (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) could reverse recent losses and beat the market in 2016.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Lloyds Banking Group (LSE: LLOY) and GlaxoSmithKline (LSE: GSK) may beat the FTSE 100 this year, but both stocks look likely to end the year lower than they started. Will they bounce back next year?

GlaxoSmithKline: On the rise

Shares in Glaxo are now down by nearly 25% from the highs seen in 2013. In fairness, this weakness has been justified by the firm’s recent financial performance, which has been disappointing.

Glaxo’s post-tax profits plunged from £5.436bn in 2013 to just £2.756bn in 2014 as the impact of patent losses on key products affected sales.

However, the situation does seem to be improving. Glaxo has now completed a major asset swap with Novartis and last week announced a new deal to acquire additional HIV products. Analysts expect full-year profits to rise by 34% to £3.691bn this year, and by a further 11% to £4.099bn in 2016.

The firm has managed to avoid cutting its dividend so far and currently offers a prospective yield of 6.1% for 2016. Big long-term backers of GlaxoSmithKline, such as star fund manager Neil Woodford, have been buying more shares this year.

Mr Woodford’s view is that short-term headwinds are overshadowing the much greater long-term earning power of Glaxo’s portfolio. This is a view I share.

For investors looking for long-term income and growth, I think that now could prove to be a good time to buy GlaxoSmithKline.

Lloyds: Stock overhang

I believe that Lloyds investors are suffering from a problem that more commonly affects shareholders in small cap companies – a stock overhang.

The overhang comes in the form of the government, which is gradually pumping its Lloyds shares back into the market. Since the end of May, the Treasury has sold 9% of Lloyds shares. That’s equivalent to £5.2bn worth of shares at today’s price.

This means that big institutional buyers of the stock have been guaranteed a good supply of Lloyds shares, without pushing up the price.

However, the share sale has been paused recently as Lloyds shares have been selling below 73.6p. This is the price at which the government bailed out Lloyds in 2008. The bankers handling the sale have been told only to sell Lloyds stock when the price is above this level.

I suspect that this requirement means Lloyds’ share price will find support at around 70p, as the volume of shares available for institutions to buy is much lower now that the government isn’t selling.

However, I also suspect that Lloyds shares won’t rise much above 73.6p until the government has sold all of its shares, which it hopes to do in 2016.

That’s why I believe now could be a good time to buy. At today’s price of 72p, Lloyds offers a prospective yield of 5.1% for 2016, and a modest forecast P/E of 9.5. The shares are supported by a book value of 68p and by 55p per share of tangible assets.

In my view Lloyds currently offers more upside potential than downside risk, and could prove a profitable buy for 2016.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Can someone invest like Warren Buffett with a spare £500?

Christopher Ruane explains why an investor without the resources of billionaire Warren Buffett could still learn from his stock market…

Read more »

Investing Articles

Can these 2 incredible FTSE 250 dividend stocks fly even higher in 2026?

Mark Hartley examines the potential in two FTSE 250 shares that have had an excellent year and considers what 2026…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Is 45 too late to start investing?

Investing at different life stages can come with its own challenges -- and rewards. Our writer considers why a 45-year-old…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

UK shares look cheap — but the market might be about to take notice

UK shares have traded at a persistent discount to their US counterparts. This can create huge opportunities, but investors need…

Read more »

Investing Articles

This FTSE 100 growth machine is showing positive signs for a 2026 recovery

FTSE 100 distributor Bunzl is already the second-largest holding in Stephen Wright’s Stocks and Shares ISA. What should his next…

Read more »

Investing Articles

I asked ChatGPT for the best FTSE 100 stocks to buy for passive income in 2026 and it said…

Paul Summers wanted to learn which dividend stocks an AI bot thinks might be worth buying for 2026. Its response…

Read more »

ISA Individual Savings Account
Investing Articles

Stop missing out! A Stocks and Shares ISA could help you retire early

Investors who don't use a Stocks and Shares ISA get all the risks that come with investing but with less…

Read more »

Investing Articles

Will Greggs shares crash again in 2026?

After a horrible 2025, Paul Summers takes a look at whether Greggs shares could sink even further in price next…

Read more »